These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32805212)

  • 1. Targeting the 5-HT system: Potential side effects.
    Hoyer D
    Neuropharmacology; 2020 Nov; 179():108233. PubMed ID: 32805212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of serotonin receptor subtypes in treating depression: a review of animal studies.
    Carr GV; Lucki I
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):265-87. PubMed ID: 21107537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain.
    Moreau X; Jeanningros R; Mazzola-Pomietto P
    Neuropsychopharmacology; 2001 Jun; 24(6):652-62. PubMed ID: 11331145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Developments on Future Antidepressant-related Serotonin Receptors.
    Amidfar M; Kim YK
    Curr Pharm Des; 2018; 24(22):2541-2548. PubMed ID: 30073919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists.
    Gray JA; Roth BL
    Brain Res Bull; 2001 Nov; 56(5):441-51. PubMed ID: 11750789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors.
    Orús L; Pérez-Silanes S; Oficialdegui AM; Martínez-Esparza J; Del Castillo JC; Mourelle M; Langer T; Guccione S; Donzella G; Krovat EM; Poptodorov K; Lasheras B; Ballaz S; Hervías I; Tordera R; Del Río J; Monge A
    J Med Chem; 2002 Sep; 45(19):4128-39. PubMed ID: 12213056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter.
    Butler SG; Meegan MJ
    Curr Med Chem; 2008; 15(17):1737-61. PubMed ID: 18673223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of 5-HT(2) receptors in the tryptamine-induced 5-HT syndrome in rats.
    Van Oekelen D; Megens A; Meert T; Luyten WH; Leysen JE
    Behav Pharmacol; 2002 Jul; 13(4):313-8. PubMed ID: 12218512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review.
    Gillman PK
    Headache; 2010 Feb; 50(2):264-72. PubMed ID: 19925619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of 5-HT(2B) receptors in the serotonin syndrome.
    Diaz SL; Maroteaux L
    Neuropharmacology; 2011 Sep; 61(3):495-502. PubMed ID: 21277875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular remodeling and the peripheral serotonergic system.
    Ayme-Dietrich E; Aubertin-Kirch G; Maroteaux L; Monassier L
    Arch Cardiovasc Dis; 2017 Jan; 110(1):51-59. PubMed ID: 28017279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Side effects and proper usage of anxiolytics].
    Cho Y; Okubo M
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():242-6. PubMed ID: 18072342
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
    Bang-Andersen B; Ruhland T; Jørgensen M; Smith G; Frederiksen K; Jensen KG; Zhong H; Nielsen SM; Hogg S; Mørk A; Stensbøl TB
    J Med Chem; 2011 May; 54(9):3206-21. PubMed ID: 21486038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs.
    DeBattista C; Sofuoglu M; Schatzberg AF
    Biol Psychiatry; 1998 Sep; 44(5):341-7. PubMed ID: 9755356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting 5-HT receptors for the treatment of obesity.
    Sargent BJ; Henderson AJ
    Curr Opin Pharmacol; 2011 Feb; 11(1):52-8. PubMed ID: 21330209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.
    Marek GJ; Carpenter LL; McDougle CJ; Price LH
    Neuropsychopharmacology; 2003 Feb; 28(2):402-12. PubMed ID: 12589395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions.
    Diaz SL; Doly S; Narboux-Nême N; Fernández S; Mazot P; Banas SM; Boutourlinsky K; Moutkine I; Belmer A; Roumier A; Maroteaux L
    Mol Psychiatry; 2012 Feb; 17(2):154-63. PubMed ID: 22158014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.
    Halberstadt AL; Geyer MA
    Neuropharmacology; 2011 Sep; 61(3):364-81. PubMed ID: 21256140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.